Welcome

OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.

Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.

OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.

DIAGNOSTIC PRODUCTS:

"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.

R&D SERVICES:

OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.

 

Company introduction

  • OWLiver - information for physicians - how it works
  • owl liver for patients - that is it - benefits - faqs
  • what is metabolomics - get to know owl technology
Events
News

11/30/2017

News

OWL CONTINÚA SU EXPANSIÓN EN MADRID CON LA IMPLANTACIÓN EN DMQ DE OWLIVER®, TEST DE DIAGNÓSTICO DE LA ENFERMEDAD HEPÁTICA GRASA NO ALCOHÓLICA.
El Centro Digestivo Médico Quirúrgica de Madrid (DMQ) es uno de los centros privados pioneros en incorporar en Madrid la nueva técnica de detección de la enfermedad de hígado graso no alcohólico (NAFLD en inglés) desarrollado por la biotecnológica ONE WAY LIVER/OWL. Este novedoso test, denominado OWLiver®, evita la biopsia hepática que, hasta el momento, ha sido el único procedimiento para el diagnóstico de esta enfermedad. El test se realiza mediante una muestra de sangre que discrimina al paciente con hígado graso del más grave con acumulación de grasa e inflamación del hígado (NASH).

 

11/23/2017

News

CIC bioGUNE y OWL Metabolomics participan en un innovador proyecto de investigación europeo para desarrollar una mejor prueba diagnóstica de la enfermedad hepática
- El objetivo del proyecto LITMUS es optimizar y validar las pruebas de diagnóstico para la evaluación temprana de los pacientes con hígado graso no alcohólico e identificar a los que tienen mayor riesgo de desarrollar inflamación severa y cirrosis

 

11/23/2017

News

OWL Metabolomics participates in one of the most innovative European research projects to develop the best diagnostic tool for liver diseases.
The Target of the Litmus Project focused to optimize and validate diagnostic tools for an early evaluation of patients with Non-Alcoholic Fatty Liver (NAFL) and to identify those with higher risk of severe inflammation and cirrhosis.

 

OWL is a trading name of
ONE WAY LIVER, S.L
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone: +34 94 431 85 40
Fax: +34 94 431 71 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 11/30/2017

With the collaboration of: